AcclaimIP-ad

Match Document Document Title
US20140314811 HERPES SIMPLEX VIRUS VACCINES  
The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
US20120263752 Herpes Simplex Virus Vaccines  
The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
US20140220106 LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS  
Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
US20110212162 LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS  
Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
US20130071429 BUNYAVIRUS VACCINE  
The present invention provides attenuated viruses for use as vaccines and for the treatment and/or prevention of viral diseases and/or infections.
US20150079123 LIVE, ATTENUATED RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS  
Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) without an in-frame deletion, a rubella structural protein ORF,...
US20120263756 VACCINES CONTAINING CANINE PARVOVIRUS GENETIC VARIANTS  
Canine parvovirus vaccines and diagnostics and methods for their use are provided. The vaccines are effective against emerging canine parvovirus variants.
US20150093404 PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF  
Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2...
US20130239853 HOT SPRING BACTERIAL STRAIN BKH1 AND PROTEIN ISOLATED THEREFROM, CONCRETE COMPOSITIONS, AND USES THEREOF  
Disclosed is a Thermoanaerobacter sp. bacterial strain (BKHI) isolated from a hot spring, a purified protein (bioremediase) isolated from bacterial strain BKH1, as well as concrete compositions...
US20110287053 Recombinant Foot and Mouth Disease Vaccine  
A foot and mouth disease virus (FMDV) vaccine and method for producing same is described wherein the N terminal portion of the FMDV polyprotein, encoding the four structural proteins, 1A, 1B, 1C,...
US20130315954 METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS  
The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus,...
US20120177675 Chimaeric Protein  
The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the...
US20130345400 IDENTIFICATION OF A HUMAN GYROVIRUS AND APPLICATIONS  
The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display...
US20130315956 NEWCASTLE DISEASE VIRUS AND THE USE THEREOF AS A VACCINE  
The present invention relates to a new Newcastle disease viruses of any genotype and novel fragments of the Newcastle disease virus genome encoding for the F and HN proteins constructed by reverse...
US20130115242 Modified Viral Strains and Method for Improving the Production of Vaccine Seeds of Influenza Virus  
Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase)...
US20110152352 SMAD PROTEINS CONTROL DROSHA-MEDIATED MIRNA MATURATION  
The invention, in some aspects, relates to compositions and methods useful for modulating expression of miRNAs that are regulated by the TGF-β/BMP signaling pathway. In some aspects, the invention...
US20100297085 Synthetic Herpes Simplex Viruses Type-1 for Treatment of Cancers  
A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral γ1 34.5 genes and other immediate early genes, which render the virus able to...
US20120114619 PROTEIN WITH PROMOTING EFFECTS FOR AXONAL GROWTH OF NEURONS OF CENTRAL NERVOUS SYSTEM  
This invention comprises a polypeptide, a recombinant vector, a recombinant organism as well as RNA- and DNA-sequences. Furthermore, the use of polypeptides and recombinant vectors is described....
US20120171243 METHOD OF PREPARING LIVE VIRAL VACCINES BY GENETIC ENGINEERING OF VIRAL GENOME  
Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a...
US20120117673 GENETIC ENCRYPTION  
The present invention relates to a method to engineer either the genome of a genetically modified organism, other bioengineered reagent, or in vitro translation system for protein synthesis from...
US20100330038 METHODS FOR EXPRESSING PROTEINS IN AXONS  
The invention relates to expressing proteins in the axons of mammalian polypeptide in neuronal axons, viruses that can be used deliver nucleic acids of the invention into neuronal axons, as well...
US20110305726 Infectious Bronchitis Vaccines Derived From IB-qx-like Vaccine Strains  
The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX,...
US20140294892 CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS  
The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
US20130171189 INDUCIBLE AND REPRESSIBLE VACCINIA VIRUSES WITH IMPROVED SAFETY  
Described herein are recombinant vaccinia viruses that provide the efficacy of the current smallpox vaccine, but with a built-in safety mechanism, giving the physician or vaccine recipient...
US20120195928 VACCINES AND METHODS FOR USING THE SAME  
Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments...
US20140010840 RECOMBINANT MUMPS VIRUS VACCINE  
The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/us/06. Further, a reverse genetics system was constructed and used to rescue...
US20130202639 Synthetic Herpes Simplex Viruses for Treatment of Cancers  
New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed...
US20120263751 Recombinant Measles Virus Useful as a Bivalent Vaccine Against Measles and Nipah Infections  
Provided herein is a vaccine which is safe and effective against Nipah virus infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which...
US20130209499 VACCINES FOR USE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA VIRUS DISEASE  
Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their...
US20110287050 RECOMBINANT KOI HERPESVIRUS (KHV) OR CYPRINID HERPESVIRUS 3 (CYHV-3) AND A VACCINE FOR THE PREVENTION OF A DISEASE CAUSED BY KHV/CYHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI  
The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and...
US20140348875 KOI HERPESVIRUS VACCINE  
The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the...
US20130095137 PAN-LYSSAVIRUS VACCINES AGAINST RABIES  
Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or...
US20120315295 Development of a Marker Foot and Mouth Disease Virus Vaccine Candidate That is Attenuated in the Natural Host  
We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus...
US20140322704 Hepatitis Virus Culture Systems Using Stem Cell-Derived Human Hepatocyte-Like Cells and Their Methods of Use  
The invention relates to the discovery that DHH derived from stem cells are permissive for infection by hepatitis viruses (HV), such as hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis...
US20140178430 IDNA VACCINES AND METHODS FOR USING THE SAME  
Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses,...
US20150024004 FLAVIVIRUS VACCINES  
The invention provides flavivirus vaccines and methods of making and using these vaccines.
US20130189306 Flavivirus Vaccines  
The invention provides flavivirus vaccines and methods of making and using these vaccines.
US20110165683 CHIMERIC GAMMARETROVIRUS  
The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof.
US20120034262 Bovine Herpes Virus-1 Compositions, Vaccines and Methods  
The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1...
US20110158908 CYCLOSPORIN A-BINDING PROTEIN  
Disclosed are: a composition and a method for the diagnosis and/or the treatment of a CSABP-related disease, the regulation of the proliferation of an RNA virus and the regulation of an...
US20140220061 YEAST EXPRESSION OF FLAVIVIRUS VIRUS-LIKE PARTICLES AND USE THEREOF  
Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a Pichia pastoris strain...
US20100323398 Baculoviruses With Enhanced Virion Production and a Method for the Production of Baculoviruses  
The present invention provides a method for restoring budding capability to GP64null baculoviruses including gp64null AcMNPV by expressing therein a portion of the VSV G protein gene or a...
US20110014232 CHIMERIC FOOT AND MOUTH DISEASE VIRUSES  
Foot and mouth disease (FMD) viruses which are able to grow on BHK-21 cells in suspension are described herein. The new viruses are recombinant chimeric viruses formed by replacing the outer...
US20120165226 PHAGE DISPLAY  
The transformation yield of electroporation is increased by using higher DNA concentrations and DNA affinity purification. Fusion proteins of a viral coat protein variant and a heterologous...
US20130225664 METHODS AND COMPOSITIONS FOR DECREASING CHRONIC PAIN  
The present invention provides compositions and methods for the selective silencing of neurons in pain pathway by using a combination of inhibitory light-sensitive protein gene transfer and...
US20120171246 IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES  
Methods for protecting the brain and other tissues from virus-associated toxicity are provided. Patients are treated with a first immunizing virus prior to administration of a second, therapeutic...
US20120201852 Vaccines Against Japanese Encephalitis Virus and West Nile Virus  
The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.
US20130023033 PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM  
The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in...
US20110052626 LEPORIPOXVIRUS-DERIVED VACCINE VECTORS  
The invention relates to modified leporipoxyinises expressing a chimeric envelope protein resulting from the fusion of an envelope protein of mature intracellular virions or of an envelope protein...
US20100297731 Novel adenoviruses, nucleic acids that code for the same and the use of said viruses  
The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, prior to a second protein which is...